カテゴリ： 世界, 医療/バイオ, Market Monitor Global

ダビガトランのグローバル市場展望 2023年-2029年：プラダクサ、プラダクス、プラザキサ

■ 英語タイトル：Dibigatran Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8464）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8464
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：76
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[ダビガトランのグローバル市場展望 2023年-2029年：プラダクサ、プラダクス、プラザキサ]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界のダビガトラン市場規模と予測を収録しています。・世界のダビガトラン市場：売上、2018年-2023年、2024年-2029年
・世界のダビガトラン市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のダビガトラン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「プラダクサ」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

ダビガトランのグローバル主要企業は、Pfizer, Inc. (US)、 Bayer Healthcare AG (Germany)、 GlaxoSmithKline Plc. (UK)、 Boehringer Ingelheim (Germany)、 Sanofi S.A. (France)、 Abbott India Limited (India)、 Aspen Holdings (South Africa)、 Bristol-Myers Squibb Company (US)、 Eisai Inc. (US)、 Mitsubishi Tanabe Pharma Corporation (Japan)、 Teva Pharmaceutical Industries Ltd. (Israel)などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、ダビガトランのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のダビガトラン市場：タイプ別、2018年-2023年、2024年-2029年
世界のダビガトラン市場：タイプ別市場シェア、2022年
・プラダクサ、プラダクス、プラザキサ

世界のダビガトラン市場：用途別、2018年-2023年、2024年-2029年
世界のダビガトラン市場：用途別市場シェア、2022年
・脳卒中、深部静脈血栓症、肺塞栓症、全身性塞栓症

世界のダビガトラン市場：地域・国別、2018年-2023年、2024年-2029年
世界のダビガトラン市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるダビガトランのグローバル売上、2018年-2023年
・主要企業におけるダビガトランのグローバル売上シェア、2022年
・主要企業におけるダビガトランのグローバル販売量、2018年-2023年
・主要企業におけるダビガトランのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Pfizer, Inc. (US)、 Bayer Healthcare AG (Germany)、 GlaxoSmithKline Plc. (UK)、 Boehringer Ingelheim (Germany)、 Sanofi S.A. (France)、 Abbott India Limited (India)、 Aspen Holdings (South Africa)、 Bristol-Myers Squibb Company (US)、 Eisai Inc. (US)、 Mitsubishi Tanabe Pharma Corporation (Japan)、 Teva Pharmaceutical Industries Ltd. (Israel)

*************************************************************

・調査・分析レポートの概要
ダビガトラン市場の定義
市場セグメント
世界のダビガトラン市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のダビガトラン市場規模
世界のダビガトラン市場規模：2022年 VS 2029年
世界のダビガトラン市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのダビガトランの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のダビガトラン製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：プラダクサ、プラダクス、プラザキサ
ダビガトランのタイプ別グローバル売上・予測

・用途別市場分析
用途区分：脳卒中、深部静脈血栓症、肺塞栓症、全身性塞栓症
ダビガトランの用途別グローバル売上・予測

・地域別市場分析
地域別ダビガトラン市場規模 2022年と2029年
地域別ダビガトラン売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Pfizer, Inc. (US)、 Bayer Healthcare AG (Germany)、 GlaxoSmithKline Plc. (UK)、 Boehringer Ingelheim (Germany)、 Sanofi S.A. (France)、 Abbott India Limited (India)、 Aspen Holdings (South Africa)、 Bristol-Myers Squibb Company (US)、 Eisai Inc. (US)、 Mitsubishi Tanabe Pharma Corporation (Japan)、 Teva Pharmaceutical Industries Ltd. (Israel)
...

This report aims to provide a comprehensive presentation of the global market for Dibigatran, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dibigatran. This report contains market size and forecasts of Dibigatran in global, including the following market information:
Global Dibigatran Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Dibigatran Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Dibigatran companies in 2022 (%)
The global Dibigatran market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Pradaxa Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Dibigatran include Pfizer, Inc. (US), Bayer Healthcare AG (Germany), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim (Germany), Sanofi S.A. (France), Abbott India Limited (India), Aspen Holdings (South Africa), Bristol-Myers Squibb Company (US) and Eisai Inc. (US), etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Dibigatran manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Dibigatran Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Dibigatran Market Segment Percentages, by Type, 2022 (%)
Pradaxa
Pradax
Prazaxa
Global Dibigatran Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Dibigatran Market Segment Percentages, by Application, 2022 (%)
stroke
deep vein thrombosis
pulmonary embolism
systemic embolism
Global Dibigatran Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Dibigatran Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Dibigatran revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Dibigatran revenues share in global market, 2022 (%)
Key companies Dibigatran sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Dibigatran sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer, Inc. (US)
Bayer Healthcare AG (Germany)
GlaxoSmithKline Plc. (UK)
Boehringer Ingelheim (Germany)
Sanofi S.A. (France)
Abbott India Limited (India)
Aspen Holdings (South Africa)
Bristol-Myers Squibb Company (US)
Eisai Inc. (US)
Mitsubishi Tanabe Pharma Corporation (Japan)
Teva Pharmaceutical Industries Ltd. (Israel)
Outline of Major Chapters:
Chapter 1: Introduces the definition of Dibigatran, market overview.
Chapter 2: Global Dibigatran market size in revenue and volume.
Chapter 3: Detailed analysis of Dibigatran manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Dibigatran in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Dibigatran capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Dibigatran Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Dibigatran Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Dibigatran Overall Market Size
2.1 Global Dibigatran Market Size: 2022 VS 2029
2.2 Global Dibigatran Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Dibigatran Sales: 2018-2029
3 Company Landscape
3.1 Top Dibigatran Players in Global Market
3.2 Top Global Dibigatran Companies Ranked by Revenue
3.3 Global Dibigatran Revenue by Companies
3.4 Global Dibigatran Sales by Companies
3.5 Global Dibigatran Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Dibigatran Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Dibigatran Product Type
3.8 Tier 1, Tier 2 and Tier 3 Dibigatran Players in Global Market
3.8.1 List of Global Tier 1 Dibigatran Companies
3.8.2 List of Global Tier 2 and Tier 3 Dibigatran Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Dibigatran Market Size Markets, 2022 & 2029
4.1.2 Pradaxa
4.1.3 Pradax
4.1.4 Prazaxa
4.2 By Type – Global Dibigatran Revenue & Forecasts
4.2.1 By Type – Global Dibigatran Revenue, 2018-2023
4.2.2 By Type – Global Dibigatran Revenue, 2024-2029
4.2.3 By Type – Global Dibigatran Revenue Market Share, 2018-2029
4.3 By Type – Global Dibigatran Sales & Forecasts
4.3.1 By Type – Global Dibigatran Sales, 2018-2023
4.3.2 By Type – Global Dibigatran Sales, 2024-2029
4.3.3 By Type – Global Dibigatran Sales Market Share, 2018-2029
4.4 By Type – Global Dibigatran Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Dibigatran Market Size, 2022 & 2029
5.1.2 stroke
5.1.3 deep vein thrombosis
5.1.4 pulmonary embolism
5.1.5 systemic embolism
5.2 By Application – Global Dibigatran Revenue & Forecasts
5.2.1 By Application – Global Dibigatran Revenue, 2018-2023
5.2.2 By Application – Global Dibigatran Revenue, 2024-2029
5.2.3 By Application – Global Dibigatran Revenue Market Share, 2018-2029
5.3 By Application – Global Dibigatran Sales & Forecasts
5.3.1 By Application – Global Dibigatran Sales, 2018-2023
5.3.2 By Application – Global Dibigatran Sales, 2024-2029
5.3.3 By Application – Global Dibigatran Sales Market Share, 2018-2029
5.4 By Application – Global Dibigatran Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Dibigatran Market Size, 2022 & 2029
6.2 By Region – Global Dibigatran Revenue & Forecasts
6.2.1 By Region – Global Dibigatran Revenue, 2018-2023
6.2.2 By Region – Global Dibigatran Revenue, 2024-2029
6.2.3 By Region – Global Dibigatran Revenue Market Share, 2018-2029
6.3 By Region – Global Dibigatran Sales & Forecasts
6.3.1 By Region – Global Dibigatran Sales, 2018-2023
6.3.2 By Region – Global Dibigatran Sales, 2024-2029
6.3.3 By Region – Global Dibigatran Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Dibigatran Revenue, 2018-2029
6.4.2 By Country – North America Dibigatran Sales, 2018-2029
6.4.3 US Dibigatran Market Size, 2018-2029
6.4.4 Canada Dibigatran Market Size, 2018-2029
6.4.5 Mexico Dibigatran Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Dibigatran Revenue, 2018-2029
6.5.2 By Country – Europe Dibigatran Sales, 2018-2029
6.5.3 Germany Dibigatran Market Size, 2018-2029
6.5.4 France Dibigatran Market Size, 2018-2029
6.5.5 U.K. Dibigatran Market Size, 2018-2029
6.5.6 Italy Dibigatran Market Size, 2018-2029
6.5.7 Russia Dibigatran Market Size, 2018-2029
6.5.8 Nordic Countries Dibigatran Market Size, 2018-2029
6.5.9 Benelux Dibigatran Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Dibigatran Revenue, 2018-2029
6.6.2 By Region – Asia Dibigatran Sales, 2018-2029
6.6.3 China Dibigatran Market Size, 2018-2029
6.6.4 Japan Dibigatran Market Size, 2018-2029
6.6.5 South Korea Dibigatran Market Size, 2018-2029
6.6.6 Southeast Asia Dibigatran Market Size, 2018-2029
6.6.7 India Dibigatran Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Dibigatran Revenue, 2018-2029
6.7.2 By Country – South America Dibigatran Sales, 2018-2029
6.7.3 Brazil Dibigatran Market Size, 2018-2029
6.7.4 Argentina Dibigatran Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Dibigatran Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Dibigatran Sales, 2018-2029
6.8.3 Turkey Dibigatran Market Size, 2018-2029
6.8.4 Israel Dibigatran Market Size, 2018-2029
6.8.5 Saudi Arabia Dibigatran Market Size, 2018-2029
6.8.6 UAE Dibigatran Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Pfizer, Inc. (US)
7.1.1 Pfizer, Inc. (US) Company Summary
7.1.2 Pfizer, Inc. (US) Business Overview
7.1.3 Pfizer, Inc. (US) Dibigatran Major Product Offerings
7.1.4 Pfizer, Inc. (US) Dibigatran Sales and Revenue in Global (2018-2023)
7.1.5 Pfizer, Inc. (US) Key News & Latest Developments
7.2 Bayer Healthcare AG (Germany)
7.2.1 Bayer Healthcare AG (Germany) Company Summary
7.2.2 Bayer Healthcare AG (Germany) Business Overview
7.2.3 Bayer Healthcare AG (Germany) Dibigatran Major Product Offerings
7.2.4 Bayer Healthcare AG (Germany) Dibigatran Sales and Revenue in Global (2018-2023)
7.2.5 Bayer Healthcare AG (Germany) Key News & Latest Developments
7.3 GlaxoSmithKline Plc. (UK)
7.3.1 GlaxoSmithKline Plc. (UK) Company Summary
7.3.2 GlaxoSmithKline Plc. (UK) Business Overview
7.3.3 GlaxoSmithKline Plc. (UK) Dibigatran Major Product Offerings
7.3.4 GlaxoSmithKline Plc. (UK) Dibigatran Sales and Revenue in Global (2018-2023)
7.3.5 GlaxoSmithKline Plc. (UK) Key News & Latest Developments
7.4 Boehringer Ingelheim (Germany)
7.4.1 Boehringer Ingelheim (Germany) Company Summary
7.4.2 Boehringer Ingelheim (Germany) Business Overview
7.4.3 Boehringer Ingelheim (Germany) Dibigatran Major Product Offerings
7.4.4 Boehringer Ingelheim (Germany) Dibigatran Sales and Revenue in Global (2018-2023)
7.4.5 Boehringer Ingelheim (Germany) Key News & Latest Developments
7.5 Sanofi S.A. (France)
7.5.1 Sanofi S.A. (France) Company Summary
7.5.2 Sanofi S.A. (France) Business Overview
7.5.3 Sanofi S.A. (France) Dibigatran Major Product Offerings
7.5.4 Sanofi S.A. (France) Dibigatran Sales and Revenue in Global (2018-2023)
7.5.5 Sanofi S.A. (France) Key News & Latest Developments
7.6 Abbott India Limited (India)
7.6.1 Abbott India Limited (India) Company Summary
7.6.2 Abbott India Limited (India) Business Overview
7.6.3 Abbott India Limited (India) Dibigatran Major Product Offerings
7.6.4 Abbott India Limited (India) Dibigatran Sales and Revenue in Global (2018-2023)
7.6.5 Abbott India Limited (India) Key News & Latest Developments
7.7 Aspen Holdings (South Africa)
7.7.1 Aspen Holdings (South Africa) Company Summary
7.7.2 Aspen Holdings (South Africa) Business Overview
7.7.3 Aspen Holdings (South Africa) Dibigatran Major Product Offerings
7.7.4 Aspen Holdings (South Africa) Dibigatran Sales and Revenue in Global (2018-2023)
7.7.5 Aspen Holdings (South Africa) Key News & Latest Developments
7.8 Bristol-Myers Squibb Company (US)
7.8.1 Bristol-Myers Squibb Company (US) Company Summary
7.8.2 Bristol-Myers Squibb Company (US) Business Overview
7.8.3 Bristol-Myers Squibb Company (US) Dibigatran Major Product Offerings
7.8.4 Bristol-Myers Squibb Company (US) Dibigatran Sales and Revenue in Global (2018-2023)
7.8.5 Bristol-Myers Squibb Company (US) Key News & Latest Developments
7.9 Eisai Inc. (US)
7.9.1 Eisai Inc. (US) Company Summary
7.9.2 Eisai Inc. (US) Business Overview
7.9.3 Eisai Inc. (US) Dibigatran Major Product Offerings
7.9.4 Eisai Inc. (US) Dibigatran Sales and Revenue in Global (2018-2023)
7.9.5 Eisai Inc. (US) Key News & Latest Developments
7.10 Mitsubishi Tanabe Pharma Corporation (Japan)
7.10.1 Mitsubishi Tanabe Pharma Corporation (Japan) Company Summary
7.10.2 Mitsubishi Tanabe Pharma Corporation (Japan) Business Overview
7.10.3 Mitsubishi Tanabe Pharma Corporation (Japan) Dibigatran Major Product Offerings
7.10.4 Mitsubishi Tanabe Pharma Corporation (Japan) Dibigatran Sales and Revenue in Global (2018-2023)
7.10.5 Mitsubishi Tanabe Pharma Corporation (Japan) Key News & Latest Developments
7.11 Teva Pharmaceutical Industries Ltd. (Israel)
7.11.1 Teva Pharmaceutical Industries Ltd. (Israel) Company Summary
7.11.2 Teva Pharmaceutical Industries Ltd. (Israel) Dibigatran Business Overview
7.11.3 Teva Pharmaceutical Industries Ltd. (Israel) Dibigatran Major Product Offerings
7.11.4 Teva Pharmaceutical Industries Ltd. (Israel) Dibigatran Sales and Revenue in Global (2018-2023)
7.11.5 Teva Pharmaceutical Industries Ltd. (Israel) Key News & Latest Developments
8 Global Dibigatran Production Capacity, Analysis
8.1 Global Dibigatran Production Capacity, 2018-2029
8.2 Dibigatran Production Capacity of Key Manufacturers in Global Market
8.3 Global Dibigatran Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Dibigatran Supply Chain Analysis
10.1 Dibigatran Industry Value Chain
10.2 Dibigatran Upstream Market
10.3 Dibigatran Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Dibigatran Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 皮膚糸状菌症治療のグローバル市場展望 2023年-2029年：Rx、OTC
  • LNP合成原料のグローバル市場展望 2023年-2029年：植物性、動物性
  • 矯正歯科用テレデンティストリーのグローバル市場展望 2023年-2029年：非同期、同期、その他
  • 肝臓用サプリメントのグローバル市場展望 2023年-2029年：錠剤、粉末、液体
  • サラセミア治療のグローバル市場展望 2023年-2029年：DFO、DFP、DFX、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8464 )"ダビガトランのグローバル市場展望 2023年-2029年：プラダクサ、プラダクス、プラザキサ" (英文：Dibigatran Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。